[go: up one dir, main page]

BRPI0413742A - derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados - Google Patents

derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados

Info

Publication number
BRPI0413742A
BRPI0413742A BRPI0413742-6A BRPI0413742A BRPI0413742A BR PI0413742 A BRPI0413742 A BR PI0413742A BR PI0413742 A BRPI0413742 A BR PI0413742A BR PI0413742 A BRPI0413742 A BR PI0413742A
Authority
BR
Brazil
Prior art keywords
compounds
derivatives used
mitoquinone
mitochondrially targeted
targeted antioxidants
Prior art date
Application number
BRPI0413742-6A
Other languages
English (en)
Inventor
Kenneth Martin Taylor
Robin Smith
Original Assignee
Antipodean Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antipodean Pharmaceuticals Inc filed Critical Antipodean Pharmaceuticals Inc
Publication of BRPI0413742A publication Critical patent/BRPI0413742A/pt
Publication of BRPI0413742B1 publication Critical patent/BRPI0413742B1/pt
Publication of BRPI0413742B8 publication Critical patent/BRPI0413742B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)

Abstract

"DERIVADOS DE MITOQUINONA USADOS COMO ANTIOXIDANTES MITOCONDRIALMENTE ALVEJADOS". Esta invenção relaciona-se com compostos antioxidantes anfifílicos farmaceuticamente aceitáveis, composições e formas de dosagens compreendendo os referidos compostos, e métodos e usos baseados nos referidos compostos. Os compostos exemplificados são todos derivados de mitoquinona, sendo derivados de metoxifenil alquil trifenilfosfónio ou metóxi dioxociclohexadieno alquil trifenilfosfónio. Os compostos, composições, formas de dosagem, usos e métodos sejam úteis, por exemplo, no tratamento de doenças ou condições associadas com estresse oxidativo.
BRPI0413742A 2003-08-22 2004-08-23 composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante BRPI0413742B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ52780003 2003-08-22
NZ527800 2003-08-22
NZ529153 2003-10-23
NZ52915303 2003-10-23
NZ53355604 2004-06-14
NZ533556 2004-06-14
PCT/NZ2004/000196 WO2005019232A1 (en) 2003-08-22 2004-08-23 Mitoquinone derivatives used as mitochondrially targeted antioxidants

Publications (3)

Publication Number Publication Date
BRPI0413742A true BRPI0413742A (pt) 2006-10-24
BRPI0413742B1 BRPI0413742B1 (pt) 2019-05-21
BRPI0413742B8 BRPI0413742B8 (pt) 2021-05-25

Family

ID=34222195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413742A BRPI0413742B8 (pt) 2003-08-22 2004-08-23 composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante

Country Status (8)

Country Link
EP (1) EP1664069B8 (pt)
KR (1) KR100974202B1 (pt)
AU (1) AU2004266988B2 (pt)
BR (1) BRPI0413742B8 (pt)
CA (1) CA2536546C (pt)
NO (1) NO337925B1 (pt)
RU (1) RU2487880C2 (pt)
WO (2) WO2005019233A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
ES2541769T3 (es) 2003-08-22 2015-07-24 Antipodean Pharmaceuticals, Inc. Derivados de mitoquinona usados como antioxidantes dirigidos a las mitocondrias
SG156613A1 (en) * 2004-07-13 2009-11-26 Oridis Biomed Forschungs Und E Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007035496A1 (en) 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2734208C (en) 2008-03-14 2018-01-09 Jiri Neuzil Mitochondrially delivered anti-cancer compounds
JP6227856B2 (ja) 2008-04-01 2017-11-08 アントイポデアン ファーマシューティカルズ， インコーポレイテッド スキンケア用組成物及び方法
JP2012502064A (ja) 2008-09-10 2012-01-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化還元活性治療剤を用いての広汎性発達障害の処置
NZ592663A (en) * 2008-10-06 2012-08-31 Arden Elizabeth Inc Skin treatments containing carboxylic acid-substituted idebenone derivatives and methods of preparation and use thereof
WO2011108946A1 (en) * 2010-03-04 2011-09-09 Androgenix Ltd Methods for improving sperm functionality
RU2527519C2 (ru) * 2010-06-24 2014-09-10 Общество С Ограниченной Ответственностью "Митотех" Мягкие катионные митохондриальные разобщители
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
AU2012312654B2 (en) 2011-09-19 2017-04-13 Gencia Corporation Modified creatine compounds
US10806703B2 (en) 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
AU2018373053C1 (en) 2017-11-24 2021-04-01 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
AU2020210888A1 (en) * 2019-01-25 2021-08-19 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
DE102019218241A1 (de) * 2019-11-26 2021-05-27 Beiersdorf Ag Wirkstoffkombinationen aus Ubichinol und Carrageenan und kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
GB2610815A (en) * 2021-09-14 2023-03-22 Mitorx Therapeutics Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
CN1318434C (zh) * 1997-11-25 2007-05-30 安迪珀蒂恩生物工艺学有限公司 线粒体靶向的抗氧剂
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)

Also Published As

Publication number Publication date
NO20060977L (no) 2006-05-19
EP1664069A4 (en) 2009-09-30
AU2004266988B2 (en) 2011-05-26
AU2004266988A1 (en) 2005-03-03
EP1664069B1 (en) 2015-04-08
KR100974202B1 (ko) 2010-08-06
BRPI0413742B1 (pt) 2019-05-21
RU2487880C2 (ru) 2013-07-20
CA2536546A1 (en) 2005-03-03
WO2005019232A1 (en) 2005-03-03
CA2536546C (en) 2012-10-02
EP1664069B8 (en) 2015-07-01
WO2005019233A1 (en) 2005-03-03
RU2006109020A (ru) 2007-09-27
KR20070018766A (ko) 2007-02-14
EP1664069A1 (en) 2006-06-07
BRPI0413742B8 (pt) 2021-05-25
NO337925B1 (no) 2016-07-11

Similar Documents

Publication Publication Date Title
BRPI0413742A (pt) derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados
SG145715A1 (en) Mitoquinone derivatives used as mitochondrially targeted antioxidants
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
NO20070866L (no) Antivirale forbindelser.
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
BRPI0414867A (pt) pirazolopiridinas e seus análogos
AR048912A1 (es) Inmunoglobulinas anti-nogo
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
BRPI0406801B8 (pt) derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
BRPI0410170A (pt) preparação e uso de derivados de ácido aril alquìlico para o tratamento de obesidade
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2844 DE 08/07/2025 POR TER SIDO INDEVIDA.